Mira Pharmaceuticals' Ketamir-2 shows 60% greater efficacy than gabapentin in preclinical neuropathy study

MIRA PHARMACEUTICALS, INC.

Ketamir-2 demonstrated 60% greater efficacy than FDA-approved gabapentin in a preclinical model of chemotherapy-induced neuropathic pain.
Company plans additional preclinical studies targeting diabetic neuropathy and PTSD.
Exploring government funding opportunities to support the development program.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.